<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197951</url>
  </required_header>
  <id_info>
    <org_study_id>2004-001056-36</org_study_id>
    <nct_id>NCT00197951</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism</brief_title>
  <official_title>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of
      dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone
      can improve malfunctioning of these disregulated systems, thereby improving anxiety,
      depression, anhedonia, anger, and alcohol craving.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 alcohol-dependent patients will be included, once finished alcohol detoxification
      treatment.Thirty patients will receive ziprasidone treatment, in progressively increasing
      doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a
      double blind procedure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score opf SCL-90-R psychiatric symptoms scale.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol consumption (amount and frequency)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other substances consumption</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Depression</condition>
  <condition>Anger</condition>
  <condition>Anxiety</condition>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of psychiatric symptoms associated to alcoholism</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV-TR criteria for alcohol dependence disorder

          -  Age between 18 -65 years old.

          -  Score 7 or higher in the GHQ-28 scale.

        Exclusion Criteria:

          -  More than 30 days without drinking alcohol.

          -  Severe medical disorders.

          -  Psychotic or bipolar disorders severely decompensated requiring antipsychotic
             medication.

          -  Opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week
             of detoxification treatment.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Guardia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad de Conductas Adictivas//Servicio de Psiquiatría//Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 20, 2007</last_update_submitted>
  <last_update_submitted_qc>April 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2007</last_update_posted>
  <keyword>Psychiatric symptoms associated to alcoholism recovery</keyword>
  <keyword>Alcoholism treatment</keyword>
  <keyword>Alcohol craving</keyword>
  <keyword>Relapse to heavy drinking</keyword>
  <keyword>Abuse of other substances during alcoholism recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

